Abstract Vepdegestrant (ARV‐471) is a novel estrogen receptor (ER) degrader currently under clinical evaluation for the treatment of ER‐positive and HER2‐negative breast cancer. We have developed an efficient catalytic stereoselective synthetic route to produce this important compound. The key step involves a Ruthenium‐catalyzed asymmetric hydrogenation, which establishes the critical stereocenter with exceptional diastereoselectivity(>99% de). This method obviates the need for chiral chromatographic separation, thereby significantly improving the efficiency and scalability of the synthetic sequence compared to previously reported approaches.